Our Network of Board-Certified Providers
Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
If you live in the Houston Park area of El Paso, Texas, The Peptide Protocol brings physician-designed peptide therapy directly to your door. El Paso County residents receive the same structured, evidence-based approach used in landmark clinical trials: FDA-approved peptide medications introduced at low starting doses and titrated on a physician-approved schedule.
Peptide medications — including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — are prescribed by TX-licensed doctors via telehealth and delivered to your El Paso home. The structured protocol ensures optimal outcomes for residents of Houston Park and surrounding El Paso County neighborhoods.[1][2]
Medically reviewed by
Dr. Sarah Mitchell, MD, ABOM
Board-Certified in Obesity Medicine • Last reviewed: June 4, 2026
Semaglutide is marketed as Ozempic for type 2 diabetes management and Wegovy for chronic weight loss in adults with obesity or overweight. Licensed physicians design individualized titration schedules — escalating dose over 16–20 weeks — to maximize weight reduction while minimizing gastrointestinal side effects.
Tirzepatide simultaneously activates GLP-1 and GIP receptors, producing additive metabolic effects beyond those of single-agonist GLP-1 therapies. Mounjaro (type 2 diabetes) and Zepbound (obesity) require physician expertise in dual-receptor pharmacology and careful patient selection to optimize outcomes.
Landmark randomized controlled trials in the New England Journal of Medicine establish the efficacy profile of FDA-approved GLP-1 medications available to Houston Park, El Paso residents:
Telehealth prescribing of GLP-1 receptor agonists in Texas is conducted by board-certified, TX-licensed physicians through HIPAA-compliant platforms. GLP-1 medications are not DEA-scheduled controlled substances and may be prescribed via telehealth after a valid clinical evaluation.
The Peptide Protocol in Houston Park follows a structured, physician-supervised pathway from assessment through active treatment. Every phase is designed to maximize your results while ensuring safety throughout the dose escalation process.
Complete a detailed health questionnaire from your home in Houston Park. It covers your weight history, metabolic health, current medications, and goals — giving your physician everything needed to design the right peptide protocol for your body.
A TX-licensed physician reviews your assessment and conducts a telehealth consultation. They select the appropriate peptide agent, establish your titration schedule, and outline what to expect at each protocol milestone. You begin with a clear roadmap.
Your peptide medication ships from a licensed US pharmacy to your Houston Park address within 3-5 business days. Your protocol begins immediately — with scheduled physician check-ins at each dose escalation milestone to monitor your progress.
The structured Peptide Protocol serves all neighborhoods in El Paso and the surrounding area.
The Peptide Protocol is available throughout El Paso, TX — structured peptide therapy in every neighborhood.
Structured peptide therapy protocols are available in cities near El Paso through our licensed physician network.
Structured peptide therapy is available in the largest cities across Texas.
Licensed GLP-1 telehealth physicians serve neighborhoods across all major US cities, providing the same clinical-grade care available at specialty obesity medicine centers.
Local weight loss and GLP-1 providers serving the Houston Park, El Paso, TX area, based on Google Business listings.
11860 Vista del Sol Dr Suite 126, El Paso, TX 79936
5/5 ★ (24 reviews)
1300 E Rio Grande Ave
4.7/5 ★ (38 reviews)
5625 Woodrow Bean Transmountain Suite 103
4.9/5 ★ (35 reviews)
Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
The Peptide Protocol for Houston Park residents is a physician-designed, structured approach to peptide weight loss therapy. It begins with a comprehensive health assessment, selects the appropriate FDA-approved peptide medication (semaglutide, tirzepatide, or liraglutide), and follows a systematic titration schedule monitored by a TX-licensed physician through regular telehealth check-ins.
All peptide medications prescribed through The Peptide Protocol are shipped from licensed US pharmacies directly to your Houston Park home. Delivery to El Paso County typically takes 3-5 business days. No pharmacy visits required — your medication arrives with clear protocol instructions.
Patients following the structured Peptide Protocol achieve 15% average weight reduction with semaglutide and up to 22% with tirzepatide over 68-72 weeks, based on clinical trial data. Most Houston Park protocol patients begin noticing appetite reduction within the first 2 weeks and measurable weight loss by week 8.
Black Box Warning: In rodent studies, semaglutide and tirzepatide caused thyroid C-cell tumors. It is unknown whether GLP-1 receptor agonists cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. These medications are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Common side effects may include nausea, vomiting, diarrhea, constipation, abdominal pain, headache, and injection site reactions. These typically diminish as dosage is gradually escalated.
Serious side effects may include pancreatitis, gallbladder problems, kidney injury, hypoglycemia (with insulin), and allergic reactions. Consult your healthcare provider immediately if you experience severe symptoms.
Contraindications: History of medullary thyroid carcinoma, MEN 2, pancreatitis, pregnancy or breastfeeding, severe gastrointestinal disease. This is not a complete list — always discuss your full medical history with your physician.
Clinical References:
